Every year there are 466 000 new cases of invasive cervical cancer in the world, most of them in developing countries. Latin America and the Caribbean, along with Sub-Saharan Africa and Southeast Asia, exhibit some of the highest incidence rates worldwide. The incidence of cervical cancer is highest among poor women with few years of schooling, who tend to be diagnosed at advanced stages of the disease. Even when these women are screened or diagnosed, however, less than one fourth of them receive adequate follow-up and care, as shown by data from Ecuador, Paraguay, Venezuela, Peru, Bolivia, Jamaica, Nicaragua, and El Salvador (1). 3 Programs for the prevention of cervical cancer have been unsuccessful in the developing world, even in countries where cytology has been available for many years and where organized health care systems exist. In industrialized countries, however, mortality from cervical cancer has shown a dramatic decrease over the past 45 years due to periodic cytologic screening. It has been difficult and expensive for many countries to develop and maintain high quality standards for cytology, to provide full access to care for women with positive cytology results, and to accomplish high coverage with cytologic screening among middle-aged women. A recent policy analysis has shown that other screening strategies may be much more cost-effective than traditional cytologic screening (Papanicolaou or Pap smear) (2). Visual inspection of the cervix with acetic acid, which provides immediate results, can assure women undelayed treatment as well. Testing for the presence of human papillomavirus (HPV) in the uterine cervix, a condition that is necessary for the development of cervical cancer, has also shown promising results in various studies.
Dr. Bratti makes reference to the spirit of cooperation of the study population in Guanacaste. As a result of this spirit, the study had very high participation rates, and these in turn contributed to its success. The author also mentions the affordability of new effective technologies, which the public health community should clearly welcome. (Please confirm that the intended meaning has been captured.) Progress is being made in this regard by the Program for Appropriate Technology in Health (PATH), a member of the ACCP. On February 2004, PATH launched partnership with Digene Corporation, the company that produces the Hybrid Capture ® test for HPV, in order to develop low-cost, easy-to-use, culturally acceptable tests for cervical cancer screening that would be suitable for areas of the world with minimal resources and poor medical infrastructure. In addition, the research partnership between Costa Rica and NCI has opened new horizons in disease prevention with the testing of a vaccine against HPV that is expected to prevent cervical cancer. New approaches to public-private partnerships that are intended to benefit key public health programs are under way. This is an area in which the Pan American Health Organization has exercised a pioneering role through its revolving fund for immunization programs in the Americas.
The lessons learned from the Guanacaste study should move other researchers from middle-and high-income countries with research capabilities to address public health problems where they occur. Building research capacity in this fashion will make it possible to advance knowledge so that public health solutions can reach those in need and health inequities can be effectively reduced through public health initiatives. The Bill and Melinda Gates Foundation has recently partnered with the National Institutes of Health and the Foundation for the National Institutes of Health (NIH Foundation) in Bethesda, Maryland, United States of America, for the study of under-researched health problems. Subsequently, the NIH Foundation launched a worldwide consultation to identify critical scientific challenges in global health and stimulate research on diseases that constitute a major burden in the developing world. It is expected that over the coming years more research will be performed in developing countries. Researchers that are given new grants to study health problems in developing countries should look carefully at the Guanacaste experience, particularly at the key factors that made this partnership a success story.
We believe that the Organization's participation in the AACP has contributed to significant advances in a number of ways, particularly the development of appropriate screening methods, their application in public health practice, technology transfer among countries, and international cooperation within the Region. It has also helped reduce disparities in access to preventive care as part of the unfinished health agenda in our hemisphere.
